Research and Markets(http://www.researchandmarkets.com/reports/c27452) has announced the addition of to their offering.  

A brand new specialist report on the Chinese pharmaceutical market that analyses 5-year market forecasts to 2010, trends, health, pricing, intellectual property, generics, market access and traditional Chinese medicine. The report comes with 3 free quarterly updates so you remain constantly up-to-date with developments.

China, in terms of both its healthcare system and pharmaceutical market, is a nation of contradiction. As the world's most populous country, and one in possession of the fastest growing major economy in the world, the nation offers a vast array of opportunities for overseas investors, complemented by a massive potential workforce and consumer base. The government has promised large-scale investment in order to improve healthcare.

However, several factors inherent in the nation's make up undermine many of these opportunities.

China remains a very poor GDP country and pharmaceutical expenditure per capita is similar to that in Pakistan or India. Increasingly China is becoming a "2 track" country. While there are some very high quality hospitals and clinics in the big cities, in rural areas facilities are badly-equipped, drugs are in short supply and trained staff are lacking. But that's just part of the story. The role of traditional Chinese medicine in limiting the growth of western medicine, continuing issues about intellectual property protection, the dominance of "copycat" drugs, a growing AIDS problem, antibiotic resistance, the expansion of Chinese R&D and downward pressure in drug pricing are all part of the mix.

Never before has there been such a need for an analysis which looks at the facts and interprets the trends. The Challenge of the Chinese Pharmaceutical Market provides all you need to know to make an informed judgement.

Key Areas Addressed:

- 5-year market forecast to 2010
- Analysis of trends
- Health provision and plans
- Health Funding
- Pricing & Reimbursement
- Intellectual Property
- Generic Drugs
- Market Access
- Traditional Chinese Medicine

Companies mentioned in the report include:

- Chindex
- Hainan Kangtong Pharmaceutical Co Ltd.
- Sincer Pharmchem Ltd
- Sinochem Jiangsu Suzhou Import Export Corp
- Tianjin Medicines & Health Products Import & Export Corp
- Anhui Anke Biotech
- Changzhou Siyao Pharmaceuticals Co. Ltd
- China Pharmaceutical Enterprise
- Dragon Pharmaceuticals
- Fuzhou Antibiotic Group Corp
- Heshuo Ephedrine Factory
- Huazhong Pharmaceutical Co. Ltd
- Jiangsu Jiangan Pharmaceutical Corp Ltd
- Jiuyuan
- Ningbo Jierfu Pharmaceutical Co Ltd
- North China Pharmaceutical Huasheng Co. Ltd
- Shenzhen Pharmaceutical Factory
- Shenzhen Taitai Pharmaceutical Industry (Taitai)
- Wenzhou Pharmaceutical Factory
- Xiamen No.2 Pharmaceutical Factory
- Xi'an Pharmaceutical Factory
- Yiyuan Pharmaceutical Co Ltd
- Allergan
- Antibioticos
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Pharmaceutical Co. (China)
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson
- Laboratories Servier
- Merck KGaA
- Merck Sharp & Dohme
- Novartis
- Novo Nordisk
- Pfizer
- Ranbaxy
- Rexim SA (Degussa)
- Roche
- Sankyo
- Sanofi-Synthelabo
- Schering-Plough
- Takeda
- Tanabe
- Valeant Pharmaceuticals
- Watson
- Yamanouchi

For more information visit http://www.researchandmarkets.com/reports/c27452

Contact Research and Markets Laura Wood Fax: +353 1 4100 980 press@researchandmarkets.com